Dong H Lee1, Jungsu S Oh1, Jee H Ham1, Jae J Lee1, Injoo Lee1, Phil H Lee1, Jae S Kim2, Young H Sohn2. 1. From the Department of Neurology (D.H.L., J.H.H., J.J.L., P.H.L., Y.H.S.) and the Severance Biomedical Science Institute (P.H.L.), Yonsei University College of Medicine; and the Department of Nuclear Medicine (J.S.O., I.L., J.S.K.), Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea. 2. From the Department of Neurology (D.H.L., J.H.H., J.J.L., P.H.L., Y.H.S.) and the Severance Biomedical Science Institute (P.H.L.), Yonsei University College of Medicine; and the Department of Nuclear Medicine (J.S.O., I.L., J.S.K.), Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea. yhsohn62@yuhs.ac jaeskim@amc.seoul.kr.
Abstract
OBJECTIVE: Olfactory dysfunction is present in the majority of patients with early-stage Parkinson disease (PD) and can precede the onset of motor symptoms by many years. We performed this study to evaluate whether normosmic patients with PD had different clinical features compared to hyposmic patients. METHODS: We analyzed the data of 208 de novo patients with PD (mean age, 65.4 ± 9.7 years; range, 38-85 years; 104 men) who underwent both olfactory function tests and dopamine transporter (DAT) scans. RESULTS: Normosmic patients were significantly younger and had fewer motor deficits than hyposmic patients with PD. Striatal subregional DAT activities were comparable between the 2 groups, but intersubregional gradients were significantly higher in normosmic than hyposmic PD. A general linear model showed that normosmic patients with PD showed significantly fewer motor deficits after controlling the patient's age, sex, symptom duration, and DAT activity in the posterior putamen (p = 0.016). Levodopa-equivalent dose at approximately 2.5 years follow-up tended to be lower in normosmic than in hyposmic PD (p = 0.055). CONCLUSIONS: These results suggest that normosmic PD is a unique clinical phenotype with a more benign course, compared to hyposmic PD. Either less pathologic involvement in the olfactory system or a greater potential for olfactory neurogenesis in normosmic PD may contribute to this benign process compared to hyposmic PD.
OBJECTIVE: Olfactory dysfunction is present in the majority of patients with early-stage Parkinson disease (PD) and can precede the onset of motor symptoms by many years. We performed this study to evaluate whether normosmic patients with PD had different clinical features compared to hyposmic patients. METHODS: We analyzed the data of 208 de novo patients with PD (mean age, 65.4 ± 9.7 years; range, 38-85 years; 104 men) who underwent both olfactory function tests and dopamine transporter (DAT) scans. RESULTS: Normosmic patients were significantly younger and had fewer motor deficits than hyposmicpatients with PD. Striatal subregional DAT activities were comparable between the 2 groups, but intersubregional gradients were significantly higher in normosmic than hyposmic PD. A general linear model showed that normosmic patients with PD showed significantly fewer motor deficits after controlling the patient's age, sex, symptom duration, and DAT activity in the posterior putamen (p = 0.016). Levodopa-equivalent dose at approximately 2.5 years follow-up tended to be lower in normosmic than in hyposmic PD (p = 0.055). CONCLUSIONS: These results suggest that normosmic PD is a unique clinical phenotype with a more benign course, compared to hyposmic PD. Either less pathologic involvement in the olfactory system or a greater potential for olfactory neurogenesis in normosmic PD may contribute to this benign process compared to hyposmic PD.
Authors: Jacob Haugen; Martijn L T M Müller; Vikas Kotagal; Roger L Albin; Robert A Koeppe; Peter J H Scott; Kirk A Frey; Nicolaas I Bohnen Journal: J Neural Transm (Vienna) Date: 2016-02-24 Impact factor: 3.575
Authors: Seok Jong Chung; Han Soo Yoo; Yang Hyun Lee; Hye Sun Lee; Byoung Seok Ye; Young H Sohn; Hunki Kwon; Phil Hyu Lee Journal: Hum Brain Mapp Date: 2019-05-14 Impact factor: 5.038
Authors: Xiuli Dan; Noah Wechter; Samuel Gray; Joy G Mohanty; Deborah L Croteau; Vilhelm A Bohr Journal: Ageing Res Rev Date: 2021-07-27 Impact factor: 11.788